10-Q: Tenon Medical Reports First Quarter 2024 Results, Revenue Up 66% Year-Over-Year

Tenon Medical's first quarter 2024 results show a significant increase in revenue, driven by a 42% rise in surgical procedures using their Catamaran System, despite ongoing losses and concerns about their ability to continue as a going concern.

Summary

• Tenon Medical reported a 66% increase in revenue for the first quarter of 2024, reaching $719,000, compared to $433,000 in the same period last year.
• The increase in revenue was primarily due to a 42% rise in the number of surgical procedures using the Catamaran System.
• The company's gross profit improved significantly, moving from a loss of $47,000 in Q1 2023 to a profit of $470,000 in Q1 2024.
• Operating expenses decreased by 18% year-over-year, totaling $3.976 million in Q1 2024, down from $4.839 million in Q1 2023.
• Net loss for the quarter was $3.576 million, an improvement from the $4.830 million loss in the same quarter of the previous year.
• The company's cash and cash equivalents stood at $4.388 million as of March 31, 2024, up from $2.428 million at the end of 2023.
• Tenon Medical has an accumulated deficit of $58.6 million as of March 31, 2024.
• The company has raised $2.605 million through a private placement of Series A Preferred Stock and warrants.
• There is substantial doubt about the company's ability to continue as a going concern for the next twelve months.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is strong revenue growth and improved gross profit, the significant net losses, going concern warning, and Nasdaq compliance issues create a negative sentiment overall. The need for further capital raises also adds to the uncertainty.

Positives

• The company experienced a significant increase in revenue, driven by higher sales volume of the Catamaran System.
• Gross profit improved substantially, indicating better cost management and pricing.
• Operating expenses decreased, suggesting improved efficiency in operations.
• The company successfully raised capital through a private placement, strengthening its cash position.
• The company reduced its net loss compared to the same quarter last year.

Negatives

• The company continues to operate at a net loss, with a loss of $3.576 million for the quarter.
• There is substantial doubt about the company's ability to continue as a going concern for the next twelve months.
• The company has an accumulated deficit of $58.6 million.
• The company received a notice from Nasdaq for not maintaining a minimum closing bid price of $1.00 per share.

Risks

• The company's ability to continue as a going concern is uncertain due to ongoing losses and negative cash flows.
• The company may not be able to raise sufficient additional capital through public or private equity offerings, debt financings, or collaborations.
• Failure to regain compliance with Nasdaq's minimum bid price rule could lead to delisting of the company's stock.
• The company faces risks related to competition in the medical device industry and the need to adapt to changes in technology and customer behavior.
• The company's future revenue is uncertain and dependent on the adoption of the Catamaran System by clinicians.

Future Outlook

The company plans to raise additional capital through public or private equity offerings, debt financings, and collaborations to fund its operations and working capital requirements. There is substantial doubt about the company's ability to continue as a going concern for the next twelve months.

Management Comments

• Management believes that the implant design and procedure they have developed, along with the 2D and 3D protocols for proper implantation, will be well-received by the clinician community.
• Management expects to incur additional operating losses and negative cash flows from operations in the foreseeable future as the Company continues its product development programs and the commercialization of The Catamaran System.

Industry Context

The company operates in the competitive medical device industry, specifically in the market for sacroiliac joint fusion systems. The company is focused on addressing the underserved market for SI joint disorders that cause lower back pain. The company's product, the Catamaran System, is positioned as a less invasive approach to SI joint fusion.

Comparison to Industry Standards

• Tenon Medical's revenue growth of 66% year-over-year is a positive sign, but it is important to compare this to the growth rates of other medical device companies in the spinal implant sector.
• Companies like Medtronic and Stryker, which are much larger, have established market positions and significant resources, making direct comparisons challenging.
• Smaller companies like SI-BONE, which also focuses on SI joint fusion, may provide a more relevant benchmark for growth and market penetration.
• Tenon's gross margin improvement is a positive trend, but it needs to be sustained and compared to industry averages to assess its competitiveness.
• The company's ongoing losses and concerns about its ability to continue as a going concern are significant issues that need to be addressed to achieve long-term sustainability.

Stakeholder Impact

• Shareholders face significant risk due to the company's going concern uncertainty and potential delisting from Nasdaq.
• Employees may be concerned about the company's financial stability and future prospects.
• Customers (clinicians) may be hesitant to adopt the Catamaran System due to the company's financial challenges.
• Suppliers and creditors face increased risk due to the company's financial instability.

Next Steps

• The company needs to regain compliance with Nasdaq's minimum bid price rule by November 4, 2024.
• The company plans to raise additional capital to fund its operations.
• The company will continue to focus on the commercialization of the Catamaran System.

Key Dates

Keywords

medical devices, sacroiliac joint fusion, Catamaran System, spinal implants, revenue growth, financial results, going concern, capital raise, Nasdaq, Series A Preferred Stock